Payment overview · 2025
General Payments
$335.29
20 reported records · 8 companies
Healthcare provider profile · identity verified
Matthew J. Timm, MD
Allopathic & Osteopathic Physicians|Family Medicine · PENDER, NE · NPI 1952345167
Verified facts
What the public records show
CMS Open Payments records show Matthew J. Timm, MD received $335.29 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 50.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $167.90 | 50.1% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.61 | 13.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $31.39 | 9.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.10 | 8.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.67 | 5.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.72 | 4.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.05 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.85 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $335.29 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $148.46 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $101.33 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $31.39 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.10 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.44 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
293 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 646 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 555 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 502 | 82 |
| Losartan Potassium | Losartan Potassium | 429 | 81 |
| Sertraline Hcl | Sertraline Hcl | 373 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 352 | 64 |
| Furosemide | Furosemide | 349 | 75 |
| Omeprazole | Omeprazole | 347 | 80 |
| Lisinopril | Lisinopril | 305 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 295 | 62 |
| Eliquis | Apixaban | 293 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 286 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 61 |
| Gabapentin | Gabapentin | 262 | 56 |
| Potassium Chloride | Potassium Chloride | 209 | 43 |
| Metformin Hcl | Metformin Hcl | 202 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 28 |
| Donepezil Hcl | Donepezil Hcl | 166 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 166 | 35 |
| Carvedilol | Carvedilol | 160 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 154 | 37 |
| Allopurinol | Allopurinol | 153 | 32 |
| Prednisone | Prednisone | 149 | 55 |
| Simvastatin | Simvastatin | 146 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 33 |
| Glimepiride | Glimepiride | 131 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 129 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 19 |
| Mirtazapine | Mirtazapine | 100 | 17 |
| Metformin Hcl Er | Metformin Hcl | 97 | 23 |
| Memantine Hcl | Memantine Hcl | 94 | 15 |
| Finasteride | Finasteride | 92 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 92 | 15 |
| Spironolactone | Spironolactone | 89 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 22 |
| Jardiance | Empagliflozin | 87 | 13 |
| Celecoxib | Celecoxib | 85 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 85 | 16 |
| Tramadol Hcl | Tramadol Hcl | 84 | 24 |
| Warfarin Sodium | Warfarin Sodium | 83 | 16 |
| Ozempic | Semaglutide | 80 | 13 |
| Montelukast Sodium | Montelukast Sodium | 79 | 17 |
| Ezetimibe | Ezetimibe | 77 | 14 |
| Meloxicam | Meloxicam | 76 | 16 |
| Alprazolam | Alprazolam | 75 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 14 |
| Farxiga | Dapagliflozin Propanediol | 56 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 56 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 52 | suppressed |
| Dutasteride | Dutasteride | 52 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Pregabalin | Pregabalin | 41 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 12 |
| Lorazepam | Lorazepam | 40 | 13 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Cephalexin | Cephalexin | 37 | 28 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Clonazepam | Clonazepam | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 23 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Digoxin | Digoxin | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 21 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 18 |
| Aimovig Autoinjector | Erenumab-Aooe | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 15 |
| Methimazole | Methimazole | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Invokana | Canagliflozin | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Estradiol | Estradiol | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $335.29 · 20 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, INSPIRE, JARDIANCE, NURTEC ODT, Ozempic, QULIPTA, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error